BEST AVAILABLE COPY




FIGURE 1

2/12

Peptide	set 1,	a.a. 1-	-20		
1 2 3 4 5 6	MEPVD MEPVD MEPVD MEPVD MDPVD DPGTV	PRLEP PKLEP PNLEP PNLEP PSLEP EPKPL	WKHPG WKHPG WKHPG WNHPG WNHPG HPERK	SQPKT SQPRT SQPKT SQPKT QMPWS	(SEQ ID NO. 16) (SEQ ID NO. 17) (SEQ ID NO. 18) (SEQ ID NO. 19) (SEQ ID NO. 20) (SEQ ID NO. 21)
Peptide	set 2,	a.a. 16	5-35		
7 8 9 10 11 12	SQPKT SQPRT SQPKT SQPKT TCCQK	ACTNC ACTSC ACNNC ACNKC ACNTC NKCPT	YCKKC YCKKC YCKNC YCKKC YCKKC	CFHCQ CFHCY CFHCY SYHCL CYHCQ FSAYC	(SEQ ID NO. 22) (SEQ ID NO. 23) (SEQ ID NO. 24) (SEQ ID NO. 25) (SEQ ID NO. 26) (SEQ ID NO. 27)
Peptide	set 3,	a.a. 31	L-50		
13 14 15 16 17	CFHCQ CFHCQ CFHCY SYHCL CYHCQ QTIKC	VCFMT VCFIT ACFTR VCFQT VCFLN MGRFH	KALGI KGLGI KGLGI KGLGI KGLGI	SYGRK SYGSK SYGRK SYGRK SYGRK YCVKS	(SEQ ID NO. 28) (SEQ ID NO. 29) (SEQ ID NO. 30) (SEQ ID NO. 31) (SEQ ID NO. 32) (SEQ ID NO. 33)

FIGURE 2A

3/12

Peptide	set 4,	a.a. 46	5-65				
19 20 21 22 23 24	SYGRK SYGSK SYGRK SYGRK SYGRK QKRHR	KRRQR KRRQR KRRQR KRRQR KRRQR QHTGR	RRAHQ RRPPQ RRAPQ RSAPP RSAPP AQYRS	NSQTH DNQTH DSQTH SSEDH SNGDH RSKRN	(SEQ (SEQ (SEQ (SEQ (SEQ	ID NO. ID NO. ID NO. ID NO. ID NO. ID NO.	34) 35) 36) 37) 38) 39)
Peptide	set 5,	a.a. 61	80				
25 26 27 28 29 30	NSQTH CNQTH DSQTH SSEDH SNGDH HSSDT	QASLS QVSLS QASLS QNLIP QNPIS LTGQS	KQPTS KQPSS KQPAS KQPLP KQPLP PRSAQ	QSRGD QPRGD QSRGD RTQGD QTRGD SNQKQ	(SEQ (SEQ (SEQ (SEQ (SEQ	ID NO. ID NO. ID NO. ID NO. ID NO. ID NO.	40) 41) 42) 43) 44) 45)
Peptide	set 6,	a.a. 76	5-95				
31 32 33 34 35	QSRGD QPRGD QSRGD RTQGD QTRGD	PTGPK PTGPK PTGPT PTGSE PTGSK	ESKKK ESKKK ESKKK ESKKE	VERET VERET VERET VESKT VESKT	(SEQ (SEQ (SEQ (SEQ	ID NO. ID NO. ID NO. ID NO. ID NO.	46) 47) 48) 49) 50)
36	KDKTG	EKPRK	GRSTS	EQPEV	(SEQ	ID NO.	51

FIGURE 2B

BEST AVAILABLE COPY

4/12

								ge	
	9607	9	961	16	961	22	961	34 g	
Unmodified Tat	9.3						:		
or in loanea lai		1.3	- 3		4 2	2.5	1	2	
Peptide set 1	9.2	11.2	: 3				, r +	3	
•		3	i, č			<u>, 4</u>		- 4	
	0.0	0.0	0.0	2.2 0.0	0.0	0.0	0.0	0.0 6	control
	0.0	0.0	0.0	0.0	0.0		0.0	0.0 7	••••••
	00	00		0/4	0.2	02	00	0008	
Peptide set 2	0.0		0:4	0.7	@.1	0,0	0.0	009	
	0.0	00	0.7	0.8	00	0.0	00	00 10	
	00	00	1.1	Ý, Ž,	0.4		0.0	0.00	
	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0 12	control
	522400 E	00	1.5		0.7	90 10 Est	00	00 13	
Peptide set 3	####60 400 %	0.0	9.561	<u>0/2</u>	0M 0.4	2 0.5	(0)(0) (0)(0)	0.0 15	
•	522300	0.0	0.1		0.3	03	· · · · · · · · · · · · · · · · · · ·	0.0 16	
	97 SOO	00			074	Committee of the contract of t	· 00	030 17	
	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0 18	control
	-0.0	0.0	4	1.5	0:5	0,5	00	0.8 19	
Dentide set 4	2500	00	14	19		36 (0.0	, , ,	20	
Peptide set 4	335200 E	0,0	and the same	->≃@(f	And the second second second second	45 A 15 A		21	
	0.1	00		02	02	Secretary of the second	0.5	0.6 22 0.5 23	
		000	0.0	0.0	0.3 0.0	0.3	0.0	0.0 24	control
	0.0	0.0 0.6	O.U	2.5	0.0	5.0	0.0	2.3 25	control
	206	04			08	10 1	02	26	
Peptide set 5	* * OO	0.0		23	? ହ	4(5	11 17	<u>0</u> @ 27	
	0.0	0,0	04	QI	<u>- مي ا</u>	-(0,1)	00	00 28	
	00		0.4	05	-0,1	405	00	0୍ଧ 29	
	0.0	0.0	0,0	0,0	0.0	0.0	0.0	0.0 30	control
	1.2	्रिंडी,				ingen ye day (1871 - 1871 - 1871 - 1871 - 1871 - 1871 - 1871 - 1871 - 1871 - 1871 - 1871 - 1871 - 1871 - 1871	2.2	31	
Peptide set 6	38 (41) (6 44)	16			· · · · · · · · · · · · · · · · · · ·	22.0 23.00	2.c 3.c	32 3.5 33	
•	2 14 5 6 00	00 8	0.3	03	1,5		03		
	0.4	0/4	6.6	1.L	2.8	ાહ	0.9	077 35	
	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0 36	control


FIGURE 3A

							e e				
	95011	96	96032 95042		960)58	960	061	Peptide		
Tat toxoid		3			5.6	- T				1	
					_ ; ;	2.5		1. 2	- 27	2	
Peptide set 1				- 3					43	3	
	المراكبة المسلمان	8 23		• • •				119	* **	4	
		. L			8.1	2 8				2	
		0.0			0.0			0.0	0.0		control
		K) 0/6			-02			-୧୭.୩			
Pontido not 3	7.00) ()			40 30	0.3	0.4	<0.5			
Peptide set 2		10 7 -011		Bearing the Comment	40X)		200			10	
	T. W. C. L. C.	0.4		444	-0,9		24.5 -0.1	00			
	***************************************	10 0.6			≥0,{j 0.0		0.0	0.0	0.0		control
		0.0 0.0	4		0.0				0.0		Control
	(4(0)) (4(4))		A		E T 0 2	0.2	0.2	0.5	0.5		
Peptide set 3	Annie manne de la companya del la companya de la co	10 0.2			12 0.2			0.3	0.5		
r cplide set o		(0 0.2 (0 0.2		-	031	0.8	Acceptance and the second		0.1		
	The state of the s	(d) 0.2		The second second second	102		0.9	0.2	0.2		
		.0 0.0		The state of the s	0.0		0.0	0.0	0.2		control
	1400								624 0.1		CONTROL
				Macoro	65/0			50 0.7			
Dontido not 4	The state of the s	เกีย				 		0.3	0.3		
Peptide set 4		10 - 202			₹08			0.3	0.3		
	THE RESERVE OF THE PERSON OF T	10 22 02			32.03		- 02				
		.0 0.0			0.0	0.0	0.0	0.0	0.0		control
		0 2000		1	(0!0	0.0		c0.1			001111101
		00			and the second second second second	0.0	Commence of the Commence of th	-01	0.0		
Peptide set 5	Contract of the contract of	00			0.0	0.0	0.0		रंग्डी		
r epade set s		0.0		**************************************	2500	0.0	Ø% (0!0	E0201	338 C OS	0.00	
		0 0		(mm)	1 1 0 0		£ 600	7			
	Name and Association of the Control	.0 0.0			0.0	0.0	0.0	0.0	0.0	30	control
		0.00						MATE ON			
	20 00000 - 16 1 0 10 0000	191 (0)		0.4	0.3		00	***************************************			
Peptide set 6	0.0	0 -01			0.0		3 00	9-01		33	
, cpude oct o	20.0			(0) 0		0.2	200		Section Indicated the Section		
	000				0.1		• 100	0.2	37 02	35	
	0	0 0	-		0			0	0	36	control

O.D. 1 6 1 22 0.5 to 0.999 0.2 to 0.499 0.10 0.1991

FIGURE 3B








FIGURE 4A




FIGURE 4B




FIGURE 5




FIGURE 6A

B




FIGURE 6B




FIGURE 6C

12/12




FIGURE 7